Translational research: A phase I study of niraparib and pimitespib in patients with solid tumor

Translational research: A phase I study of niraparib and pimitespib in patients with solid tumor - NiraPim TR Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030220300

Enrollment

Registered

2022-08-27

Start date

2022-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable recurrent solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Willing to participate in the "A phase I study of niraparib and pimitespib in patients with solid tumor (jRCT2031220179)". 2) Written consent has been obtained from the patient for this ancillary study. 3) Age 18 years or older on the date consent is obtained.

Exclusion criteria

Exclusion criteria: 1) Patients who are regarded as inappropriate for enrollment by investigators.

Design outcomes

Primary

Measure	Time frame
Correlation of objective response rate or disease control rate with biomarkers	—

Secondary

Measure	Time frame
Progression-free survival, duration of response, duration of treatment success, correlation of biomarkers with overall survival, etc.	—

Contacts

Public ContactHiromichi Nakajima

National Cancer Center Hospital East

nirapim_core@east.ncc.go.jp+81-4-7133-1111

Outcome results